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Abstract
Bone mass loss is a major complication of chronic cholestatic liver disease (CCD). However, the long-term impact of CCD on 
bone mass acquisition is unknown. We longitudinally assessed bone mineral density (BMD) and factors involved in bone remod-
eling in 9 children and adolescents with CCD Child-Pugh A (5 boys/4 girls) and in 13 controls (6 boys/7 girls). The groups were 
evaluated twice, at baseline (T0) and after 3 years (T1), when osteocalcin, deoxypyridinoline, 25-hydroxyvitamin-D, parathyroid 
hormone, insulin-like growth factor-I (IGF-I), and BMD (L1-L4, proximal femur and total body) were determined. Serum levels 
of receptor activator for nuclear factor kB ligand (RANKL) and osteoprotegerin were measured only at T1. Lumbar spine BMD 
was reanalyzed twice: after adjustment for bone age and to compensate for the height factor. Volumetric density was also es-
timated mathematically in L2-L4. The BMD of L1-L4 was lower in the CCD group (Z-score at T0: control = -1.2 ± 0.8 vs CCD = 
-2.2 ± 1.4, P < 0.05; T1: control = -0.7 ± 0.8 vs CCD = -2.1 ± 1.1, P < 0.05). Osteocalcin and deoxypyridinoline were similar for 
the two groups. The CCD group presented lower IGF-I (Z-score at T1: control = 1.4 ± 2.8 vs CCD = -1.5 ± 1.0, P < 0.05) and 
RANKL (control = 0.465 ± 0.275 vs CCD = 0.195 ± 0.250 pM, P < 0.05) than control. Children with compensated CCD Child-
Pugh A showed early impairment of bone acquisition, with the impact being more severe in an initial phase and then tapering 
in a slowly progressive way. Reduction in endocrine IGF-I has a crucial role in this process.
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Hepatic osteodystrophy is one of the most important 
extra-liver expressions of chronic hepatic disease and rep-
resents the final result of several mechanisms contributing 
to bone fragility. The most relevant factors are nutritional 
changes, hormonal disorders and the metabolic environ-
ment inherent to the progressive deterioration of liver func-
tion (1-4). Regarding this last factor, cholestasis is used as 
a specific indicator determining bone involvement in chronic 
liver disease (5). 
Although hepatic osteodystrophy may involve two osteo-
metabolic disorders, osteoporosis and osteomalacia, over 
the last few years, evidence indicates that osteoporosis is 
the most important component of this disorder (6,7). We 
recently observed that, even in the early stage of chronic 
cholestatic disease (CCD), bone mass development is 
impaired in children (8). However, the design of the previ-
ous study was cross-sectional and therefore unsuitable 
for evaluating the evolution of bone mass of patients with 
this disease.
Recently, the receptor activator for nuclear factor kB 
(RANK), its ligand (RANKL) and osteoprotegerin (OPG), 
which belong to the tumor necrosis factor (TNF) and TNF 
receptor superfamily, have emerged as a major molecular 
mechanism by which the osteoblasts modulate the activity 
of the osteoclasts. Stimulators of bone resorption increase 
RANKL expression in osteoblasts, and some also decrease 
OPG expression (9,10). However, the relevance of serum 
RANKL and OPG levels has been questioned since it seems 
that the circulatory levels of these factors do not reflect the 
condition of the tissue microenvironment (11). Unexpectedly, 
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high OPG levels have been found to be correlated with age 
and were significantly higher in osteoporotic women com-
pared to age-matched controls (11). However, there are few 
studies in the literature regarding the role of serum RANKL/
OPG in children and, until today, there are no data about 
these factors in children with cholestatic liver disease.
The present study was conducted to determine the 
evolution of hepatic osteodystrophy in pediatric subjects by 
assessing: 1) possible changes in mineral metabolism by 
biochemical determination of serum calcium, phosphorus, 
magnesium, 25-hydroxyvitamin D (25-OH-D), and parathy-
roid hormone (PTH) levels; 2) bone mineral density (BMD) 
and biochemical bone remodeling parameters such as 
osteocalcin and deoxypyridinoline (DPD), and 3) the pattern 
of endocrine insulin-like growth factor-I (IGF-I) levels and 
their influence on the progression of this bone disorder. In 
addition, in the second evaluation we assessed the serum 
levels of osteoprotegerin/RANKL.
Material and Methods
The study was approved by the Ethics Committee of 
Faculdade de Medicina de Ribeirão Preto, Universidade de 
São Paulo (Protocol #6974/05). Parents or persons legally 
responsible for the children gave written informed consent 
for participation in this study.
In our first study conducted in 2004-2005, we evalu-
ated 36 children and adolescents, 13 of them with CCD 
(77% with low bone mass) and 23 controls (8). Of the 23 
control subjects, 10 moved to other addresses. Most of 
these individuals are children of migrant rural workers, a 
fact that prevented us from locating them, with 13 control 
subjects being left in the study. Of the 13 CCD children, 
4 were excluded (2 of them died during the observation 
period, 1 was submitted to hepatic transplantation and 1 
could not be located), leaving 9 CCD subjects. The present 
study corresponds to a reevaluation of the remaining group 
3 years later (T1). The basal period (T0) contemplates only 
results of those individuals able to participate in the sec-
ond evaluation. Thus, in the current study the CCD group 
consisted of 9 children and adolescents, 5 boys and 4 girls 
with a mean age of 10.0 ± 5.5 years and a median age of 
9.7 years. The etiology of liver disease was extrahepatic 
bile duct atresia in 5 individuals, ductal hypoplasia in 2, 
choledochous cyst in 1, and Alagille syndrome in 1. The 
severity of liver disease for all patients was classified as 
Child-Pugh A. The control group consisted of 13 healthy 
children and adolescents, 6 boys and 7 girls with a mean 
age of 10.6 ± 3.2 years and a median of 8.4 years and with 
normal height for age (Table 1). The control individuals had 
no personal history of metabolic disease, acute or chronic 
disorders, and were not taking any drugs interfering with 
bone and mineral metabolism. They were recruited at the 
Puericulture Outpatient Clinic of the Medical Center of Vila 
Lobato, FMRP, Ribeirão Preto, among those routinely fol-
lowed up for pediatric medical care.
The diagnosis of CCD was based on clinical criteria 
(history of cholestatic liver disease of more than 6 months 
duration) and/or a liver biopsy. CCD patients were treated 
daily with an oral polyvitamin supplement (1000 IU ergo-
calciferol, 5000 IU vitamin A, 80 mg vitamin C, and 15 mg 
vitamin E) and also with parenteral vitamin K replacement 
at 15- to 30-day intervals depending on prothrombin time. 
These patients were being followed at the outpatient clinic 
of Pediatric Gastroenterology, Centro Médico Universitário, 
Faculdade de Medicina de Riberirão Preto, USP.
Children with osteometabolic disease not related to 
liver disease and those taking medications affecting bone 
mineral metabolism (estrogens, corticosteroids, diuretics, 
anticonvulsants) were excluded. All children admitted to 
the study had normal kidney function.
A peripheral blood sample was collected after an over-
night fast and immediately processed to obtain serum and 
aliquots were stored in a freezer at -70°C. A sample of the 
second void urine was collected under standardized con-
ditions at 8:00-9:00 am. An aliquot was immediately used 
for creatinine determination and a second one was stored 
frozen at -70°C. Liver function was evaluated by the following 
biochemical tests: alanine aminotransferase (ALT; normal 
range (NR) = 0-44 U/L), aspartate aminotransferase (AST; 
NR = 0-34 U/L), alkaline phosphatase (NR = 65-650 U/L), 
gamma-glutamyltransferase (γGT; NR = 7-50 U/L), albumin 
(NR = 35-50 g/L), total protein (NR = 40-60 g/L), total bilirubin 
(NR = 0.0-20.52 µM), and direct bilirubin (NR = 0.0-5.13 
µM). The analyses were performed using an automatic 
biochemical analyzer (KoneLab 60, WINER, Argentina). The 
prothrombin test (NR = 10.1-13.7 s) was also performed, 
with determination of the international normalized ratio by 
the clotting test using an automatic analyzer (STA Compact, 
Stago, USA). The Child-Pugh criterion modified for chronic 
cholestasis was used for the classification of the severity 
of chronic liver disease (12).
Serum levels of total calcium (NR = 2.12-2.62 mM) and 
inorganic phosphorus were assessed with an automatic bio-
chemical analyzer (Dimension RXL, Dade-Behring, USA). 
The serum levels of magnesium were determined by atom 
absorption spectrophotometry (Perkin Elmer Apparatus, 
USA). Osteocalcin was measured by an immunoradiometric 
(IRMA) method (DSL-7600, USA). Urinary DPD was mea-
sured by an immunoenzymatic (ELISA) assay (Metra, USA). 
The intra-assay coefficient of variation (CV) for osteocalcin 
and DPD was 3.3 and 2.1%, respectively. Serum 25-OH-D 
was measured by radioimmunoassay (DiaSorin, Italy), CV 
= 6.1%. Serum PTH was measured by chemoluminescence 
(Diagnostic Products Corporation, USA), CV = 3.2%, and 
IGF-I was measured by IRMA (DSL-5600, Diagnostic Sys-
tems Laboratories, USA), CV = 9.6%. OPG and RANKL 
were determined by ELISA (Biomedica, Austria) with an 
intra-assay CV of 2.3 and 4.4%, respectively.
Scans of lumbar spine (L1-L4), total hip and femoral 
Hepatic osteodystrophy in children 1129
www.bjournal.com.br Braz J Med Biol Res 43(11) 2010
neck BMD, as well as total body lean and fat mass were 
determined by double-energy X-ray emission (Hologic 
4500W, USA). The exams were performed according to 
rigid positioning criteria standardized for each target site, 
by the same operator. BMD results are reported as areal 
BMD (g/cm2) and Z-score. The Z-score was re-evaluated, 
taking into account adjustment for bone age. In addition, 
volumetric density of the lumbar spine (aBMD) was also 
estimated mathematically in L2-L4 as proposed by Carter 
et al. (13), using the following equation: aBMD = α/β, where 
α is BMD (in g/cm2) of the lumbar spine (L2-L4) and β is 
the square root of bone area (in cm2) of the lumbar spine 
(L2-L4). 
The precision errors of BMD measurements were 1.2% 
for the lumbar spine (L1-L4), 1.9% for the femoral neck, and 
2.9% for the total femur. Low BMD was defined using the 
criteria of the International Society of Clinical Densitometry, 
i.e, a Z-score of -2.0 or less adjusted for age and gender 
(14). Bone age was determined by the method of Graulich-
Pyle, as described (8).
Laboratory and BMD data were analyzed statistically by 
the Multilevel test (random and fixed effects) and regression 
models were constructed using the PROC MIXED software 
(SAS version 8.0, USA). The standard deviation score of 
IGF-I, expected values for age, was calculated according to 
manufacturer information. Data regarding the comparison of 
alkaline phosphatase, BMD, bone mineral content (BMC), 
lean mass and fat mass at T0 and T1 in each subject were 
analyzed by the parametric paired Student t-test. (15).
Results
The clinical characteristics of both groups are given in 
Table 1. There were no significant differences in age, weight 
or height between groups at T0 and T1. However, when 
height was expressed as a Z-score, the values were signifi-
cantly higher in the control group at both evaluations.
Serum albumin levels were normal in both groups, but 
the values were higher in the control group than in the CCD 
group at both T0 and T1 (Table 1). The serum levels of liver 
enzymes (AST, ALT, γGT, and alkaline phosphatase) were 
higher in the CCD group than in the control group at T0 and 
T1, although serum AST and ALT levels decreased from 
T0 to T1. A different pattern was observed regarding serum 
levels of alkaline phosphatase, since both groups presented 
higher serum levels at the last evaluation (Table 1). The 
patients with cholestasis showed lower serum magnesium 
levels than the control group at T1.
Both groups showed normal serum levels of 25-OH-D 
during the study. Vitamin D values were higher in the CCD 
group compared to the control group at first evaluation, 
but this difference was no longer observed at T1. Only 
one CCD patient presented vitamin D deficiency (serum 
level <25.0 nM). Serum PTH levels were similar for the two 
groups at the first evaluation, but increases of 87 and 47% 
were observed in the CCD and control group, respectively, 
at the second evaluation. Thus, at T1, the serum levels 
of PTH were significantly higher in the CCD group (7.9 ± 
3.5 pM) compared to the control group (5.0 ± 2.2 pM; P < 
0.05; Table 1).
The parameters of bone remodeling, i.e., osteocalcin 
and urinary DPD, were similar for the two groups at T0. The 
control group showed a stronger tendency to an increase 
in serum osteocalcin levels, but there were no differences 
between groups at the end of the study. Only the CCD group 
showed a tendency to an increase in the urinary levels of 
DPD at T1 (Table 1). 
Serum OPG levels were similar for the two groups. 
Circulating RANKL levels were significantly lower in the 
CCD group (0.2 ± 0.2 pM) as compared to the control group 
(0.4 ± 0.2 pM; P < 0.05) and the OPG/RANKL ratio was 
significantly higher in the CCD group (Table 1). 
The control group showed higher serum IGF-I levels 
than the cholestatic patients, with values being signifi-
cantly higher at T1 (control = 64.1 ± 44.9 vs CCD = 19.8 
± 24.1 nM; P < 0.05). In addition, when IGF-I levels were 
expressed as Z-score, the values were significantly higher 
in the control group than in the CCD group at both T0 and 
T1 (Figure 1).
At T1, both groups showed a significant increase in 
BMD and BMC of the lumbar spine [e.g., BMC: CCD (T0 
= 14.9 ± 9.9 and T1 = 20.2 ± 11.4 g; P < 0.05) vs control 
(T0 = 20.4 ± 11.2 and T1 = 29.3 ± 13.7 g; P < 0.05). The 
increase corresponded to 35.6 and 43.6% in the CCD 
and control groups, respectively. The Z-score values of 
the lumbar spine were significantly higher in the control 
group at T0 (control = -1.2 ± 0.8 vs CCD = -2.2 ± 1.4; P < 
0.05) and T1 (control = -0.7 ± 0.8 vs CCD = -2.1 ± 1.1; P 
< 0.05). The pattern of the bone Z-score was maintained 
when the bone age of both groups was considered (T0: 
control = -0.9 ± 1.0 vs CCD = -2.3 ± 0.9; P < 0.05 and T1: 
control = -1.0 ± 0.6 vs CCD = -1.8 ± 0.9; P < 0.05). In the 
first evaluation, 77.7% of the CCD group and 15.3% of the 
control group presented low bone mass (Z-score ≤2.0). At 
T1, the rate of low bone mass was 0% for the control group 
and 66% for the CCD group. The estimated aBMD tended 
to increase in the control group (T0 = 0.106 ± 0.022 and 
T1 = 0.109 ± 0.017 g/cm3) and to decrease in the CCD 
group (T0 = 0.099 ± 0.021 and T1 = 0.095 ± 0.022 g/cm3). 
Although aBMD values were higher in the control group at 
both times (T0 and T1), the differences between groups 
were not significant.
Total hip and femoral neck BMD values did not differ 
between groups at T0. An increase in these parameters, 
which was more evident in the control group, was observed 
during the study period. Thus at T1, the values of femoral 
neck BMD were significantly higher in the control group than 
in the CCD group (control = 0.753 ± 0.11 vs CCD = 0.597 
± 0.121 g/cm2; P < 0.05; Table 2). Total hip BMD was not 
significantly higher in the control group compared to the 
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CCD group (Table 2).
Lean mass, fat mass and fat percent were slightly higher 
in the control group than in the CCD group at T0 and T1. 
Lean mass increased by 32.9% in the CCD group (T0 = 
16383.8 ± 9150.2 vs T1 = 21782.9 ± 10883.9 g; P < 0.05) 
and by 43.4% in the control group (T0 = 18133.2 ± 6390.8 
g vs T1 = 26009.9 ± 7667.8 g; P < 0.05) while fat mass 
increased by 63.3% in the control group (T0 = 6136.6 ± 
4757.2 g vs T1 = 10024.0 ± 4322.0 g; P < 0.05) and by 
16% (T0 = 6300.7 ± 6979.0 vs T1 = 7329.2 ± 5797.6 g; P 
= 0.17) in the CCD group. Compared to T0, percent body 
fat decreased by 5.3% in the CCD group and increased by 
14.4% in the control group at T1 (Table 2). 
Both groups presented a positive correlation between 
IGF-I and BMD. This was observed in the CCD group in the 
total body (T0: r = 0.740, P < 0.05 and T1: r = 0.586, P < 
0.05), lumbar spine (T1: r = 0.675, P < 0.05), total hip (T0: r 
= 0.759, P < 0.05 and T1: r = 0.759, P < 0.05), and femoral 
neck (T0: r = 0.779, P < 0.05 and T1: r = 0.799, P < 0.05) 
and in the control group in the lumbar spine (T0: r = 0.76, 
P < 0.05 and T1: r = 0.56, P = 0.05). In the control group 
and in the CCD group, the aBMD of the lumbar spine was 
Table 1. Demographic characteristics and laboratory results of patients with chronic cholestatic disease 
(CCD) and the control group at first (T0) and second (T1) evaluations.
T0 T1
Control CCD Control CCD
CA (years) 7.2 ± 5.3 7.6 ± 3.4 10.6 ± 3.2 10.0 ± 5.5
BA (years) 6.7 ± 5.6 7.0 ± 4.0 10.7 ± 3.4 8.9 ± 5.3
Weight (kg) 23.5 ± 15.8 26.0 ± 10.3 38.7 ± 9.0 30.0 ± 16.7
Height (cm) 112.0 ± 25.5 125.4 ± 16.4 144.3 ± 16.4 126.8 ± 20.5
Z-score/height -1.2 ± 0.7 0.4 ± 0.9* 0.4 ± 0.9 -1.1 ± 0.9*
AST (NR = 0.0-34.0 U/L) 44 ± 41.7 93.2 ± 53.3* 23.8 ± 6.2 55.8 ± 34.4*
ALT (NR = 0.0-44.0 U/L) 36.6 ± 16.3 97.3 ± 46.6* 21 ± 24.3 44.1 ± 24.3*
γGT (NR = 7.0-50.0 U/L) 21.8 ± 5.3 171.4 ± 134.2* 22.3 ± 3.1 77.9 ± 68.2*
AP (NR = 65-650 U/L) 242.7 ± 70.2 530.0 ± 250.8*+ 638.9 ± 209.0 1115.5 ± 748.0*+
TP (NR = 40-60 g/L) 74 ± 3 73 ± 6 68 ± 5 68 ± 4
ALB (NR = 35-50 g/L) 46 ± 2 42 ± 4* 43 ± 2 39 ± 4*
TB (NR = 0.0-20.52 μM) 29.0 ± 39.3 30.7 ± 32.4
DB (NR = 0.0-5.13 μM) 18.8 ± 35.9 13.6 ± 17.1
Bile acids 63.8 ± 93.0
PT (NR = 10.1-13.7 s) 1.0 ± 0.1 1.1 ± 0.9
Ca (NR = 2.12-2.62 mM) 2.3 ± 0.07 2.3 ± 0.07 2.0 ± 0.02 2.3 ± 0.17*
Pi (NR = 0.80-1.80 mM) 1.5 ± 0.19 1.5 ± 0.25 1.7 ± 0.16 1.5 ± 0.06
Mg (NR = 0.53-0.88 mM) 0.5 ± 0.06 0.5 ± 0.03 0.7 ± 0.2 0.5 ± 0.16*
Osteocalcin (nM) 41.3 ± 10.2 41.3 ± 9.9 72.8 ± 38.6 54.3 ± 19.8
DPD (nM creat.) 28.7 ± 30.3 23.6 ± 8.8 28.3 ± 10.4 31.9 ± 24.1
Vitamin D (nM) 43.0 ± 8.3 61.8 ± 26.8* 56.0 ± 31.0 58.3 ± 36.8
PTH (NR = 1.15-7.05 pM) 3.4 ± 1.6 4.2 ± 1.8 5.0 ± 2.2 7.9 ± 3.5*
IGF-I (nM) 19.9 ± 18.6 6.9 ± 8.0 64.1 ± 44.9 19.8 ± 24.1*
OPG (pM) 0.7 ± 0.6 0.6 ± 0.3
RANKL (pM) 0.465 ± 0.275 0.195 ± 0.250*
OPG:RANKL 0.14 ± 0.15 0.39 ± 0.3*
CA = chronological age; BA = bone age; AST = aspartate aminotransferase; NR = normal range; ALT = 
alanine aminotransferase; γGT = γ-glutamyltransferase; AP = alkaline phosphatase; TP = total protein; ALB 
= albumin; TB = total bilirubin; DB = direct bilirubin; PT = prothrombin time; Ca = calcium; Pi = phosphorus; 
Mg = magnesium; DPD = urinary deoxypyridinoline; PTH = parathormone; IGF-I = insulin-like growth factor-
I; OPG = osteoprotegerin; RANKL = receptor activator for nuclear factor kB ligand. *P < 0.05 compared to 
control [multilevel test (random and fixed effects)]. +P < 0.05 compared to T0 of the same group (parametric 
paired Student t-test).
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also positively correlated to IGF-I (T0: r = 0.769, P < 0.05) 
(T1: r = 0.700, P < 0.05), respectively. We did not detect a 
correlation of serum bilirubin, bile acid, PTH, vitamin D, or 
osteocalcin with BMD at T0 or T1 in either group. There was 
a positive correlation between the OPG:RANKL ratio and 
serum DPD levels in the CCD group (r = 0.717, P < 0.05), 
whereas no correlation was observed between RANKL or 
OPG levels and bone densitometry measurements.
Discussion
The risk of fracture for adults of any population is deter-
mined by the interaction between genetic and environmental 
factors throughout life and mainly depends on factors limiting 
peak bone mass. Genetic factors determine 60 to 80% of 
the variation in bone mass (16). However, environmental 
factors such as nutrition, life style and systemic diseases 
may also have a significant effect on this process (17). 
The etiopathogeny of hepatic osteodystrophy is not fully 
understood. During the terminal phase of slowly progres-
sive liver disease, hepatic osteodystrophy is the result of a 
set of factors that are being incorporated along the process 
of declining hepatic function (2,18): a) nutritional factors 
(anorexia, weight loss, changes in body composition, and 
vitamin D deficiency) (18); b) hormonal factors (hypogonad-
ism (18), vitamin D (17) and IGF-I deficiencies (8,18); c) 
metabolic alterations typical of hepatic insufficiency (acid-
base disequilibrium, disorders of intermediate metabolism, 
and cholestasis) (18), and d) inflammatory state (production 
of cytokines and interleukins) (19). The present study shows 
Figure 1. Insulin-like growth factor-I (IGF-I) Z-scores for the 
control group and for the group of individuals with chronic chole-
static disease (CCD) at first (T0) and second (T1) evaluations. 
*P < 0.05 compared to the control group (multilevel test, random 
and fixed effects).
Table 2. Bone mineral density of the lumbar spine of patients with chronic cholestatic disease (CCD) and the 
control group at the first (T0) and second evaluations (T1).
T0 T1
Control CCD Control CCD
Lumbar spine 
BMD (g/cm2) 0.549 ± 0.159 0.461 ± 0.158 0.663 ± 0.157+ 0.545 ± 0.165+
BMC (g) 20.4 ± 11.2 14.9 ± 9.9 29.3 ± 13.7+ 20.2 ± 11.4+
Z-score -1.2 ± 0.8 -2.2 ± 1.4* -0.7 ± 0.8 -2.1 ± 1.1*
Z-score/BA -0.9 ± 1.0 -2.3 ± 0.9* -1.0 ± 0.6 -1.8 ± 0.9*
BMD vol. (g/cm3) 0.106 ± 0.022 0.099 ± 0.021 0.109 ± 0.017 0.095 ± 0.022
Total hip
BMD (g/cm2) 0.669 ± 0.133 0.571 ± 0.160 0.768 ± 0.135 0.643 ± 0.152
Femoral neck
BMD (g/cm2) 0.659 ± 0.114 0.545 ± 0.158 0.753 ± 0.11 0.597 ± 0.121* 
Body composition
BMD (g/cm2) 0.703 ± 0.096 0.636 ± 0.156 0.775 ± 0.088 0.693 ± 0.133
BMC (g) 875.7 ± 375.7 744.5 ± 508.7 1251.0 ± 401.4 978.1 ± 537.8
Lean mass 18113.2 ± 6390.8 16383.8 ± 9150.2 26009.9 ± 7667.8 21782.9 ± 10883.9
Fat mass 6136.6 ± 4757.2 6300.7 ± 6979.0 10024.0 ± 4322.0 7329.2 ± 5797.6
%Fat 23.6 ± 9.1 24.5 ± 7.9 27 ± 8.6 23.2 ± 6.5
BMD = bone mineral density per area; BMC = bone mineral content; BA = bone age; BMD vol. = L2-L4 volumetric 
BMD. *P < 0.05 compared to control (multilevel test, random and fixed effects). +P < 0.05 compared to T0 of the 
same group (parametric paired Student t-test).
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that long-term impairment of bone mass development occurs 
even in children with mild and functionally compensated 
hepatic disease. Additionally, our data indicate that chronic 
hepatic underproduction of IGF-I has a pivotal role in the 
limitation of bone mass accrual in CCD. 
In a previous cross-sectional study, we observed that 
10 of 13 children and adolescents (77%) with Child-Pugh 
A and B cholestasis had a low bone mass for their ages in 
the lumbar spine (Z-score below -2.0). Furthermore, this 
pattern was maintained after the evaluation with adjustment 
for bone age and volumetric density. In the current study, 9 
children were longitudinally evaluated, all of them classified 
as compensated Child-Pugh A and it was observed that 
almost 70% presented low bone mass 3 years after the 
first evaluation. In contrast, of the 13 control subjects who 
were reevaluated about 3 years after the first assessment, 
all those who had low bone mass for their age developed a 
normal Z-score. The data show that the impairment of bone 
mass development in CCD is not due to delayed maturation. 
The CCD group presented lower bone mass than the control 
group, even after the BMD data were adjusted for bone 
age. In addition, in order to minimize the influence of bone 
size by the measurement of areal bone density, volumetric 
density was estimated mathematically in the lumbar spine. 
During the 3-year period, a trend to an increase in aBMD 
was observed in the control group as well as a decrease in 
the CCD group was observed. The control group presented 
a non-significantly higher volumetric lumbar BMD than 
the CCD group. Furthermore, the control group showed a 
tendency to an increase in volumetric BMD, whereas the 
CCD group exhibited a tendency to a decrease in volumetric 
lumbar spine density after 3 years.
In the present study, children and adolescents with 
cholestasis maintained a clinically compensated condition, 
with ALT, AST and γGT levels actually being lower at the last 
evaluation as compared to the initial levels. Nevertheless, 
the patients did not show recovery of bone mass. On the 
contrary, the data suggested a slower gain of bone mass 
compared to control, most likely implying a slow but progres-
sive impairment of the accrual of peak bone mass.
No association between bilirubin levels and BMD was 
detected. These data contrast with in vitro studies dem-
onstrating that serum with hyperbilirubinemia reduced the 
mitogenic activity of osteoblast-like cells (5). Some clinical 
studies also showed that osteoporosis is more frequent in 
cholestatic patients than in non-cholestatic patients with 
liver disease (18-20). However, the present data agree 
with previous clinical and experimental studies that did 
not detect an association between cholestasis and bone 
mass loss (21,22). Possibly, hyperbilirubinemia impacts on 
bone mass development and maintenance when advanced 
hepatic dysfunction is established. 
Although early studies have suggested that disorders of 
mineralization may be an important component of hepatic 
osteodystrophy (23-25), later studies did not reproduce 
these findings. Indeed, Long et al. (23) and Crosbie et al. 
(26) reported that treatment with vitamin D does not prevent 
the progression of hepatic osteodystrophy in adults. The 
present study shows that children and adolescents with 
CCD have a significant limitation of bone mass develop-
ment even when their serum 25-OH-D levels are maintained 
within normal limits. In addition, an association between 
serum 25-OH-D levels and bone mass was not observed in 
these patients. During the study, the CCD patients showed 
a significant increase in serum PTH levels. In addition to the 
low calcium intake by these patients (27), another aspect to 
be considered is the possibility of increased PTH fragments 
detected by the second-generation PTH assays, which were 
used in the present study. The liver is an important site of 
peripheral PTH metabolism (28,29), but PTH clearance in 
chronic liver disease has not been determined.
The RANK/RANKL/OPG system is a molecular link 
by which the osteoblasts modulate osteoclastogenesis 
and bone resorption (30,31). The osteoblasts express 
the RANKL membrane receptor and thereby interact with 
RANK, present in pre-osteoclasts and osteoclasts, and 
then stimulate cell differentiation and osteolytic activity, 
respectively. In addition, the osteoblasts may produce OPG, 
which inactivates RANKL. The determination of circulating 
levels of soluble RANKL and OPG in situations of bone 
catabolism does not always reflect the pattern expected 
at the tissue level whereby the hyperexpression of RANKL 
leads to osteoporosis and the increased production of OPG 
prevents bone loss (32). Grigorie et al. (33) detected in-
creased serum OPG levels in postmenopausal women with 
osteoporosis. In addition, there are data showing a negative 
correlation between serum OPG levels and forearm BMD 
(34). Regarding the measurement of soluble RANKL, there 
are published data showing that low serum RANKL levels 
are predictors of the risk of fracture (35).
In the present study, CCD children and adolescents 
presented OPG levels compatible with those detected in 
the control group, but their RANKL levels were significantly 
lower than control. Therefore, further studies are needed 
to determine if the reduction of serum RANKL levels in 
children may also indicate a greater risk for fracture, as 
was suggested for adults (35). Additionally, several factors 
that impair the interpretation of RANKL and OPG measure-
ments should be considered (36). OPG is also produced 
in tissues such as the skin, stomach, intestine, lung, heart, 
and placenta. In addition, enzymatic assays detect several 
fragments of circulating OPG (36). The variables that may 
interfere with the determination of soluble RANKL range 
from the instability of the molecule itself to the influence 
of physiological factors such as the menstrual cycle, age 
and gender (36).
We observed a strong association between bone mass 
and serum IGF-I levels in a previous study of cholestatic 
children (8). The present data support these data indicat-
ing that the persistent reduction of hepatic IGF-I produc-
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tion seems to be a factor that perpetuates the impairment 
of bone mass development in cholestasis. It should be 
pointed out that a recent study using an experimental 
model demonstrated that, in hepatic cholestasis, not only 
serum IGF-I levels were low, but the expression of IGF-I 
and of the GH receptor was also reduced in tibial growth 
cartilage (22). Thus, it is possible that the impaired produc-
tion not only of hepatic IGF-I, but also of IGF-I of the bone 
microenvironment (paracrine-autocrine) contributed to the 
onset of hepatic osteodystrophy. The importance of the 
endocrine and paracrine IGF-I system for the development 
and maintenance of bone mass has been demonstrated 
directly and indirectly in various experimental (37,38) and 
clinical (39) models.
Thus, the present data indicate that cholestasis is a 
disease associated with the underdevelopment of bone 
mass in children and adolescents. This can be clearly 
seen when comparing the pattern of bone mass evolution 
of the control group to that of the CCD group. In the control 
group, while children with low bone mass at the first evalu-
ation progressed to densitometric bone mass normaliza-
tion after three years, those of the CCD group continued 
to present a condition of low bone mass acquisition. The 
reduced production of hepatic IGF-I seemed to be one of 
the factors responsible for this occurrence. Further studies 
are needed to evaluate the significance of reduced serum 
RANKL levels and of the consequent increase in circulating 
OPG/RANKL levels.
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